Continuous Monitoring of Vital Signs at Home (WARD HOME II)
Launched by BISPEBJERG HOSPITAL · Oct 4, 2023
Trial Information
Current as of August 21, 2025
Recruiting
Keywords
ClinConnect Summary
The WARD HOME II clinical trial is looking into how well continuous monitoring of vital signs—like heart rate and breathing—works for patients at home. Researchers want to see how often alarms go off when these signs are outside of normal ranges and what that means for patients' health, including whether it leads to hospital visits, serious health issues, or even death within 30 days after they leave the hospital.
To participate in this study, you need to be an adult (18 years or older) who has spent at least one night in the hospital due to an acute medical condition and is ready to go home. If you've contacted emergency services but weren't admitted to the hospital after being checked by paramedics, you may also qualify. However, some individuals, like those receiving palliative care or with certain medical devices, may not be eligible. If you join the trial, you can expect to wear a wireless monitoring device at home that tracks your vital signs and alerts healthcare providers if there are any concerning changes. This could help ensure you receive timely care if needed.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult patients (≥18 years) admitted (with at least one night stay) with an acute medical disease and scheduled for discharge to their own homes
- • Adult patients (≥18 years) who have contacted the EMS and, after assessment by paramedic personnel, not deemed sick enough for immediate hospital admission.
- Exclusion Criteria:
- • Patients placed on palliative treatment.
- • Acceptable chronically abnormal vital parameters of SpO2\<88%, MAP\<70, RR\>24, or HR\>110.
- • Allergy to plaster, plastic, or silicone.
- • A pacemaker or Implantable Cardioverter Defibrillator (ICD) device.
- • If the patient was deemed not able to open the front door when visited by the investigator.
- • Inability to give informed consent.
About Bispebjerg Hospital
Bispebjerg Hospital is a leading healthcare institution located in Copenhagen, Denmark, renowned for its commitment to innovative medical research and clinical excellence. As a key sponsor of clinical trials, the hospital focuses on advancing healthcare by exploring novel therapies and treatment protocols across various medical disciplines. With a multidisciplinary team of experienced researchers and clinicians, Bispebjerg Hospital aims to enhance patient outcomes through rigorous scientific inquiry and evidence-based practices, while fostering collaboration with academic institutions and industry partners to drive progress in the medical field.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Copenhagen, Capital Region Of Denmark, Denmark
Patients applied
Trial Officials
Emilie Sigvardt, MD
Principal Investigator
Bispebjerg Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported